OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
IINN$0.4558

Inspira Technologies Oxy BHN Ltd

Advanced Medical Equipment & TechnologyVerified

Inspira Technologies Oxy BHN Ltd maintains a strong liquidity position, with $3.16 million in cash and equivalents, representing 59.1% of total assets. The company has no long-term debt and a current ratio of 1.56, indicating sufficient short-term liquidity to cover obligations. However, the firm reported negative operating and free cash flows of -$9.86 million and -$12.87 million, respectively, signaling ongoing operational cash burn. Profitability metrics are severely negative, with a net loss of $13.22 million and an operating loss of $13.62 million. Return on equity (ROE) and return on assets (ROA) are -5.69% and -2.48%, respectively, far below the industry median for advanced medical equipment firms. The company's price-to-book ratio of 8.38 and enterprise value-to-revenue ratio of 56.45 suggest a premium valuation relative to tangible asset base and revenue, despite unprofitable operations. The firm operates as a single-segment entity with no disclosed geographic revenue breakdown. This lack of diversification introduces concentration risk, as the company's performance is entirely dependent on its core product lines and regional demand. No material revenue concentration by geography or customer is reported in the latest filings. Growth prospects remain uncertain, with no revenue growth reported in the latest period. The company's operating losses and negative cash flows indicate a lack of scalable revenue generation. Analysts have assigned a mean price target of $5.00, implying a 1,000% upside from the current market price of $0.45, though this is based on a single "buy" recommendation with no supporting detail. Risk factors include liquidity risk from negative operating cash flows and dilution risk from potential future equity raises to fund operations. The firm has no immediate filing-based liquidity or dilution flags, but its capital structure shows no dilution in the current period (basic and diluted shares are equal). No adjustments were applied to valuation metrics, indicating clean financial reporting. Recent events include the publication of the latest financial snapshot, which shows continued operational losses and no material changes in capital structure. No recent filings, transcripts, or regulatory actions were identified in the available data.

30-day price · IINN-0.03 (-6.4%)
Low$0.38High$0.65Close$0.42As of13 May, 00:00 UTC
Profile
CompanyInspira Technologies Oxy BHN Ltd
TickerIINN.O
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Inspira Technologies Oxy BHN Ltd designs, develops, and commercializes advanced medical equipment and technology solutions, primarily serving the healthcare services and equipment sector.

Classification. The company is classified under the Healthcare economic sector, Healthcare Services & Equipment business sector, and Advanced Medical Equipment & Technology industry, with a confidence level of 0.92.

Inspira Technologies Oxy BHN Ltd maintains a strong liquidity position, with $3.16 million in cash and equivalents, representing 59.1% of total assets. The company has no long-term debt and a current ratio of 1.56, indicating sufficient short-term liquidity to cover obligations. However, the firm reported negative operating and free cash flows of -$9.86 million and -$12.87 million, respectively, signaling ongoing operational cash burn. Profitability metrics are severely negative, with a net loss of $13.22 million and an operating loss of $13.62 million. Return on equity (ROE) and return on assets (ROA) are -5.69% and -2.48%, respectively, far below the industry median for advanced medical equipment firms. The company's price-to-book ratio of 8.38 and enterprise value-to-revenue ratio of 56.45 suggest a premium valuation relative to tangible asset base and revenue, despite unprofitable operations. The firm operates as a single-segment entity with no disclosed geographic revenue breakdown. This lack of diversification introduces concentration risk, as the company's performance is entirely dependent on its core product lines and regional demand. No material revenue concentration by geography or customer is reported in the latest filings. Growth prospects remain uncertain, with no revenue growth reported in the latest period. The company's operating losses and negative cash flows indicate a lack of scalable revenue generation. Analysts have assigned a mean price target of $5.00, implying a 1,000% upside from the current market price of $0.45, though this is based on a single "buy" recommendation with no supporting detail. Risk factors include liquidity risk from negative operating cash flows and dilution risk from potential future equity raises to fund operations. The firm has no immediate filing-based liquidity or dilution flags, but its capital structure shows no dilution in the current period (basic and diluted shares are equal). No adjustments were applied to valuation metrics, indicating clean financial reporting. Recent events include the publication of the latest financial snapshot, which shows continued operational losses and no material changes in capital structure. No recent filings, transcripts, or regulatory actions were identified in the available data.
Key takeaways
  • Inspira Technologies Oxy BHN Ltd is a loss-making advanced medical equipment firm with a premium valuation despite negative cash flows and returns.
  • The company's liquidity position is strong in absolute terms but unsustainable given ongoing operational cash burn.
  • Analysts have assigned a high price target, but the recommendation is based on a single "buy" rating with no supporting detail.
  • The firm's lack of geographic or segment diversification introduces concentration risk.
  • No immediate liquidity or dilution flags are present, but future equity raises may be necessary to fund operations.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$289.0k
Gross profit$2.0k
Operating income-$13.6M
Net income-$13.2M
R&D
SG&A
D&A
SBC
Operating cash flow-$9.9M
CapEx-$103.0k
Free cash flow-$12.9M
Total assets$5.3M
Total liabilities$3.0M
Total equity$2.3M
Cash & equivalents$3.2M
Long-term debt$0.00
Valuation
Market price$0.45
Market cap$19.5M
Enterprise value$16.3M
P/E
Reported non-GAAP P/E
EV/Revenue56.5
EV/Op income
EV/OCF
P/B8.4
P/Tangible book8.4
Tangible book$2.3M
Net cash$3.2M
Current ratio1.6
Debt/Equity0.0
ROA-2.5%
ROE-5.7%
Cash conversion75.0%
CapEx/Revenue-35.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Equipment · cohort 91 companies
MetricIINNActivity
Op margin-4713.8%-16.5% medp25 -174.5% · p75 8.8%bottom quartile
Net margin-4574.4%-16.5% medp25 -172.4% · p75 8.4%bottom quartile
Gross margin0.7%47.4% medp25 34.2% · p75 65.3%bottom quartile
CapEx / revenue-35.6%-5.4% medp25 -12.5% · p75 -2.2%bottom quartile
Debt / equity0.0%4.3% medp25 0.0% · p75 28.0%bottom quartile
Observations
IR observations
Mean price target5.00 USD
Median price target5.00 USD
High price target5.00 USD
Low price target5.00 USD
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.11 USD
Last actual EPS-0.45 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 23:28 UTC#609eefcb
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 04:57 UTCJob: b8121dbf